InvestorsHub Logo
Followers 52
Posts 9089
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Friday, 10/13/2023 10:44:38 AM

Friday, October 13, 2023 10:44:38 AM

Post# of 13461
Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial(Saturday, October 14??, 2:25-2:35pm ET): Sandeep Basnet, MD, Director of Clinical Development at Moderna, will present data from Moderna’s phase 2 trial of its CMV vaccine.

https://www.modernatx.com/media-center/all-media/blogs/IDWeek
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News